[Successful treatment of relapse/refractory multiple myeloma with carfilzomib, lenalidomide, and dexamethasone combination therapy following allogeneic bone marrow transplantation].
Antineoplastic Combined Chemotherapy Protocols
Bone Marrow Transplantation
Dexamethasone
/ therapeutic use
Hematopoietic Stem Cell Transplantation
Humans
Lenalidomide
/ therapeutic use
Male
Middle Aged
Multiple Myeloma
/ therapy
Neoplasm Recurrence, Local
Oligopeptides
/ therapeutic use
Transplantation, Autologous
Allogeneic stem cell transplantation
Carfilzomib
Lenalidomide
Multiple myeloma
Journal
[Rinsho ketsueki] The Japanese journal of clinical hematology
ISSN: 0485-1439
Titre abrégé: Rinsho Ketsueki
Pays: Japan
ID NLM: 2984782R
Informations de publication
Date de publication:
2019
2019
Historique:
entrez:
8
11
2019
pubmed:
7
11
2019
medline:
12
11
2019
Statut:
ppublish
Résumé
A 50-year-old male was diagnosed with multiple myeloma (MM) and treated by high-dose melphalan followed by autologous stem cell transplantation in April 2014. However, he relapsed and received non-myeloablative bone marrow transplantation from an unrelated HLA-matched donor (UR-BMT) in July 2016. After 100 days of UR-BMT, the disease remained stable disease and the patient was treated with carfilzomib, lenalidomide, and dexamethaonse (KRd) therapy. After 10 cycles of KRd, he obtained stringent complete response without exacerbation of graft-versus-host disease. We concluded that KRd after allogeneic stem cell transplantation is one of the useful treatment regimens for relapsed refractory MM.
Identifiants
pubmed: 31695009
doi: 10.11406/rinketsu.60.1468
doi:
Substances chimiques
Oligopeptides
0
carfilzomib
72X6E3J5AR
Dexamethasone
7S5I7G3JQL
Lenalidomide
F0P408N6V4
Types de publication
Case Reports
Journal Article
Langues
jpn
Sous-ensembles de citation
IM